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HIV-TB COINFECTION: EXPLORING HIV-2 RESTRICTION IN 
MACROPHAGES BY INTERFERON-INDUCED EFFECTORS, GBP5 AND 
SP110 
 
DENIS SENKANDWA KYABAGGU 
ABSTRACT 
HIV and TB are among top causes of mortality and morbidity globally. Incident TB cases 
in 2015 were approximately 10.5 million, with 11% having HIV. Having HIV is also the 
biggest risk factor for developing TB disease.  
Clinical studies show HIV-2/TB coinfection cases progress to disease slower than HIV-
1/TB. However, the underlying cellular, immunological, and molecular host-pathogen 
interactions accounting for these observations remain unclear. 
The host immune response to both viral and mycobacterial infection of macrophages is 
partly dependent on type I interferon, which in turn induces expression of various 
interferon-stimulated genes (ISGs) to control the pathogens. GBP5, a GTPase with a role 
in activating the inflammasome; and Sp110, a nuclear body protein, are among various 
ISGs whose expression levels are elevated during individual viral and bacterial infections 
in macrophages. GBP5 seems to restrict HIV-1 replication in immune cells, while Sp110 
is known to restrict MTB proliferation in macrophages, but is now thought to also 
promote HIV-1 replication. We hypothesized differences in the effect of these proteins on 
the infectivity of the two HIV subtypes in macrophages. We also hypothesized that the 
viral protein Vpr is associated with the host expression levels of GBP5 and Sp110.  
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We used small hairpin RNA to knock out GBP5 and Sp110 from THP-1 human 
monocytoid cell line, differentiated using PMA into a macrophage phenotype; and 
infected these cells with GFP-expressing HIV-2 ROD 9ΔenvΔnefstrain pseudotyped with 
VSV-G envelope for single cycle infection. Percentages of macrophages infected with 
GFP-expressing viruses were measured by Flow cytometry. To determine effect of GBP5 
and Sp110 on replication of the two HIV subtypes, HIV-1 and HIV-2, we measured virus 
production in supernatants of productively infected THP-1 macrophages by titering cell-
free supernatants on TZMBl-reporter cells at day 3 and 6 post infection. 
There was a marginal increase, and a dramatic decrease, of HIV-2ΔenvΔnef GFP+ virus 
infectivity inall THP-1 macrophage conditions in the absence of viral Vpr, and Vpx, 
respectively. Knocking down macrophage Sp110 gene expression reduced single cycle 
(VSV-G pseudotyped) HIV-2 ROD 9ΔenvΔnefGFP+wild type and Vpr mutant virus 
infectivity but promoted Vpx mutant.There was a reduction in number of infectious HIV-
1 particles released from Sp110 knockdown compared to normal macrophages over 6 
days post infection; no difference in HIV-1 virus production between GBP5 knock down 
and normal macrophages in one experiment; and a decrease in HIV-1 virus production 
from GBP5 knockout compared to normal macrophages 3 and 6 days post infection in a 
follow up experiment.Interestingly, reduced Sp110 expression corresponded to increased 
HIV-2 production from macrophages in one experiment but no difference in viral 
production between normal and Sp110 knock down macrophages by day 3 post infection 
in the follow up experiment. There was no HIV-2 virus production from the Sp110 knock 
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down cells on day 6 in the follow up experiment and virus spread was reduced in GBP5 
knock down, relative to normal macrophages. 
Interestingly, reduced Sp110 expression corresponded to increased HIV-2 production 
from macrophages in one experiment, but there was no difference in viral production 
between normal and Sp110 knock down macrophages by day 3 post infection in the 
follow up experiment. There was no virus production from the Sp110 knock down cells 
on day 6 in the follow up experiment. HIV-2 virus production was also reduced in GBP5 
knock down, relative to normal, productively infected THP1/PMA macrophages. 
 
Our results support the argument that HIV-2, just like HIV-1, possibly utilizes Vpr to 
prevent sensing of virus infection in macrophages, thus allowing viral replication without 
inducing interferon stimulation, and subsequent viral restriction. Our results also suggest 
that the host macrophage restriction factor Sp110 may indeed enhance VSV-G 
pseudotyped GFP+ HIV-2 and HIV-2delVpr infectivity but restrict HIV-2 Vpx mutant. 
This could imply presence of a yet unknown association between another HIV-2 viral 
accessory protein, Vpx, and the macrophage restriction factor, Sp110 known to counter 
invading intracellular bacteria. We report much lower productive infectious virus release 
of HIV-2, compared to HIV-1, from macrophages. Overall, our results suggest that Sp110 
may transiently restrict HIV-2 infection of macrophages, but is eventually manipulated 
by the virus to promote viral replication. 
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CHAPTER 1 
INTRODUCTION 
1.1 HIV-TB Co-infection: Global Trend and Burden 
 
HIV/AIDS and TB continue to feature among the leading global causes of morbidity 
andmortality, particularly in the developing world.Of the estimated 10.4 million incident 
TB cases in 2015, 1.2 million (11%) were people living with HIV.1 HIV-TB co-infections 
accounted for approximately 22%  (400,000 deaths) of the total TB-associated mortality 
(1.8 million deaths) in 2015.1 The Africa region has the highest portion of the global burden 
of HIV-TB co-infections with 31% of TB patients living with HIV; rising to over 50% in 
parts of Southern Africa.1,2 
1.2 Challenges of Current Public Health Interventions 
Although treatment for both conditions is becoming more widely available,1,2 it is not 
curative for HIV infection. HIV-infected patients have to endure life-long treatment with 
various side-effects, whereas treatment of Mycobacterium tuberculosis (MTB) infection 
lasts several months, increasing chances of default, selection for pathogen resistance, and 
resultant treatment failure. Consequently, global HIV-TB co-infection is now complicated 
by the emergence of drug resistant strains as well as the ability for both etiologic agents to 
establish latency in the host. Furthermore, treatment of these infections in the developing 
world is largely donor-funded, not universally accessible,1,2 and therefore unsustainable, 
especially in light of the emergence of drug resistance. 
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Preventing infections may, therefore, be the more effective means of reducing, and 
eventually eliminating HIV-TB co-infection, particularly in sub-Saharan Africa - given its 
high disease burden coupled with a rapidly expanding population as well as the meagre 
fiscal, human, and infrastructure resources available for health.  
 
Among the most effective public health interventions for disease prevention and 
elimination is the development and subsequent use of vaccines. Whereas a TB vaccine has 
been available for almost a century, with good efficacy in children,3 disparate results are 
noted in older age groups;4 and, therefore, a more universally effective vaccine across all 
age groups is presently being sought.5 
The case of HIV, on the other hand is more somber: 35 years since the virus was first 
described, no effective vaccine has yet been developed. Studies aimed at understanding the 
host immune correlates of protection against both HIV and TB infection, to enable the 
subsequent development of novel vaccine candidates, are further complicated by the dearth 
of easily relatable6 and manageable animal models.7In vitro studies using human primary 
and derived cells therefore remain one of the more accessible tools for understanding the 
various host-pathogen interactions during the course of HIV-TB co-infection in human 
immune cells. 
1.3 Host Macrophage Interactions with HIV/MTB 
The lifetime risk of a healthy adult human with latent TB going on to suffer from the 
disease is only 5 - 10% for the duration of life,6,8 but is estimated to annually increase by 
between 5 – 15% in HIV infected individuals.9Innate immunity helps restrict MTB 
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virulence in humans8 and animals.7 However, the host restriction mechanism(s) in HIV-
TB co-infection is/are not well understood. 
MTBprimarily thrives in human macrophages,10 a key cell type in innate immune responses 
and in the priming of the subsequent adaptive immune response to clear pathogens. 
Compromising the immune functions of macrophagestherefore leads to wide systemic 
immune malfunction, usually resulting in severe consequences to the human host.  
On the other hand, whereas both HIV-1 and HIV-2 subtypes largely thrive in CD4+ T-
lymphocytes, the former has also been shown to infect macrophages.10 Both MTB and 
HIV-1 are also indicated to be capable of establishing latency in these 
cells11,12therebyrendering treatment suboptimal - leading to poor prognosis, particularly in 
the cases of HIV-1 infection, the more virulent of the two HIV subtypes.13 
1.4 Mechanisms of Macrophage Responses 
Both HIV and MTB illicit multiple immune reactions in macrophages.9,11,13 One of these 
is the production of pro-inflammatory cytokines, such as Type I and Type II interferons, 
which then induce the transcription of interferon stimulated genes (ISGs) such as specific 
cell type restriction factors to counter particular pathogens or their antigens.10,12,14 
1.5 ISGs as Bacterial and Viral Restriction Factors 
Of particular interest to us is the suggestion that the IFN-1 (IFN α/β)-induced speckled 110 
kDa protein (Sp110), a host nuclear body protein (orthologue of the mouse Intracellular 
Pathogen Resistance 1 gene product, also known as IPR-115) seems key in the limiting of 
transcription necessary for countering MTB infection of primary mouse as well as in, prior 
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HIV-1 infected and non-HIV-infected, human macrophages15 while concurrently 
enhancing productive HIV-1 infection when overexpressed in a human embryonic kidney-
derived HEK293T cell line.16 
This contradictory duality of host restriction factors such as Sp110 may potentially 
influence subsequent pathogenesis of HIV-TB coinfection; and could be an underlying 
explanation for reported reduced rates of clinical progress to AIDS in patients co-infected 
with HIV-2 and TB as compared to those with HIV-1-TB co-infection.17In other words, 
the infecting HIV subtype in the macrophage reservoir may influence differences in the 
expression levels of Sp110, hence influencing its restriction function against TB; and or 
the enhancement of HIV replication, thereby causing the observed differences in rates of 
progress of pathogenesis in the co-infection state. However, how Sp110 expression levels 
in macrophages may influence outcomes in response to HIV-2/MTB co-infection is 
unclear. Understanding this may provide novel avenues for developing therapeutics to 
mimic this response in patients infected with the more prevalent global HIV-1/TB, 
stemming or slowing down disease pathogenesis. 
 
Relatedly, another ISG – the guanylate binding protein 5 (GBP5) – which belongs to a 
subclass of 7 human guanylatetriphosphatases (GTPases) referred to as guanylate binding 
proteins (GBPs) of sizes 67 – 73 kDa - has been shown to be upregulated by Type I, II, and 
III IFNs.18,19GBPs are variously involved in restriction of protozoan,20 bacterial21 and 
viral22 infections; with GBP5 being among 3 whose key role in viral and bacterial immune 
responses in macrophages has been highlighted.22,23 In macrophages, GBP5 appears to 
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counter intracellular bacteria in the cytosol or in vacuoles (such as MTB) through assembly 
of the NRLP-3 inflammasome to activate caspase 1 and subsequent pro-inflammatory 
cytokine secretion18; but has also been linked to lysis of the pathogens to enhance foreign 
double stranded DNA sensing.21 On the other hand, the GBP5 antiviral mechanism seems 
to consist of interfering with RNA polymerase to reduce viral RNA and protein synthesis,18 
and its activity has been noted to restrict HIV-1, lacking the accessory genes vpu, vpr and 
nef, in macrophages through interference with viral envelope processing.22 
 
A long established fact is that chronic immune activation in HIV-1 infected individuals, 
including those on HAART, is characterized by elevated levels of pro-inflammatory 
cytokines, including type I interferon (IFN).24Further, our preliminary findings suggest that 
establishment of HIV-1 infection in macrophages and viral gene expression results in 
induction of type I IFN responses (unpublished data). HIV-2, on the other hand, seems to 
have a rather attenuated pathogenesis relative to HIV-1, even in patients co-infected with 
other pathogens such as MTB.9,12,15,17 
1.6 HIV Activation of Type-1 IFNs in Macrophages 
The two HIV subtypes marginally differ genetically; with HIV-1 having the protein Vpu 
in place of HIV-2’s Vpx (also encoded in Simian Immunodeficiency Virus, SIV).25Vpu 
(or Vpx for HIV-2) and Vpr are accessory proteins which enable viral infection of host 
cells. Vpr and Vpx are structurally similar.26 
The HIV-1 viral protein Vpr has been linked with the pathogen’s ability to evade 
detection by the innate immune sensing mechanisms by associating with the host 
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proteinDDB1-and-CUL4-associated factor 1 (DCAF-1, also called Vpr Binding Protein) 
and a yet-to-be identified host factor.27 This association is hypothesized to 
allowestablishment of viral infection in macrophages without eliciting Type 1 IFN 
secretion.27 Without interferon secretion, ISGs that play a role in limiting HIV replication 
within macrophages are not effectively induced. This effect may be more pronounced in 
viral and bacterial co-infections (such as HIV-TB) where both interferon-induced 
effectors Sp110 and GBP5 play roles during establishment of pathogen infection. Indeed 
GBP5 has been shown to restrict HIV-1 in which the accessory genes encoding Vpr,Vpu 
and nef have been deleted, while Sp110 appears to promote HIV-1, but restrict MTB, 
replication.6,15,16 
 
This may imply that HIV-2 Vprinteractions with DCAF1 and the unidentified host factor 
might not be as efficient as HIV-1 Vpr and thus unable to efficiently maskhost sensing 
and induction of type I IFN responses, thus resulting in reduced levelsof onward viral 
transmission to the more favorable CD4 T-lymphocytes. This may thus confer a 
replicative disadvantage to HIV-2 over HIV-1, resulting from a more robust host immune 
Type 1/2 IFN cytokine response to HIV-2. By extension, differentially higher levels of 
GBP5 expression; and lower ones for Sp110, in HIV-2 – TB relative to HIV-1 –TB 
coinfection in humans, may manifest in slower disease progression and tempered 
pathogenesis in the former condition. 
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We therefore sought to explore the effect of the HIV-2 accessory protein Vpr on viral 
infectivity in human-derived THP-1 macrophages in the presence and absence of the 
restriction factors GBP5 and Sp110.  
We hypothesized that HIV-2 viral infectivity of human-derived THP-1 macrophages may 
be limited by an enhanced expression of the IFN-stimulated restriction factors GBP5 and 
Sp110. We further hypothesized that enhanced expression of these two restriction factors 
during HIV-2 infection of innate immune cells, such as macrophages, depended on 
increased sensing that was unable to be suppressed by the HIV-2accessory protein Vpr. 
 
We postulate that the reported differences in immunological28,29 and clinical13,17 
outcomes associated with the infecting HIV subtype during HIV-MTB co-infection are 
related to macrophage dysregulation and or dysfunction in general; including the host 
restriction factors GBP5 and Sp110 - which possibly affect, or are affected, by the viral 
accessory protein Vpr. This compromises both innate and adaptive immunity; and in 
HIV/TB co-infection, may explain the observed differences in pathogenesis to AIDS 
between the two HIV subtypes as reported by several studies.9,10,13,15,17 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cell Culture 
All experiments were performed using a human monocytic leukemia THP-1 macrophage 
cell line, (obtained from ATCC, VA, USA) that has been previously described.30These 
are normally a non-adherent cell line, and were maintained in RPMI 1640 medium (Life 
Technologies) supplementedwith 10% FBS (Sigma-Aldrich) and 2 mmol/L L-glutamine, 
as well as 1% Penicillin/Streptomycin (Sigma-Aldrich).  
Virus stocks were made by transient transfections ofHuman Embryonic Kidney epitheial 
cell line,HEK293T (National Institute for Biological Standards and Control-NIBSC) 
while virus titers were determined in either HEK-293T or in the TZMBl cell line-a HeLa-
derived adherent cell line. Both HEK293T and the TZMBl cell lines were maintained in 
Dulbecco’s modified Eagles’s medium-DMEM (Life Technologies)supplemented with 
10% fetal bovine serum, FBS(Sigma-Aldrich) and 1% penicillin/streptomycin (Sigma-
Aldrich). All conditions were only slight modifications to previously published 
protocols.30,31 
2.2 Generating cells with knocked-out restriction factors 
Bacterial glycerol stock plasmids (Mission®) encoding shRNA transcripts for binding to, 
and degrading, the cellular mRNAs for the restriction factors GBP5 and Sp110 were 
obtained from Sigma-Aldrich (St. Louis, Missouri, USA). The shRNA plasmid sequences 
were 5’-
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CCGGCGGAAAGGAATACAGGCTGAACTGAACTCGAGTTCAGCCTGTATTCCT
TTCCGTTTTTTG-3’ for GBP5; and 5’-
CCGGCCAGAACCAAATGACCCAGAACTCGAGTTCTGGGTCATTTGGTTCTGG
TTTTT-3’ for Sp110. 
The lentiviralshRNA plasmids were co-transfected into HEK293T cells using a psPAX2 
lentivirus packaging plasmid and a vesicular stomatitis virus glycoprotein (VSV/G) 
envelope expression plasmid to yield single cycle shRNA-expressing lentiviruses, before 
subsequent infection of THP-1 cells. Sp110 or GBP5knock-out THP-1 cells were selected 
by adding 1ug/mL puromycin to the culture medium. Cell stocks were frozen down in 
liquid nitrogen at -1960 C, while working cultures were maintained in RPMI/10%FBS/1 
µg/ml puromycin at conditions prior stated, and passaged at least every 4 days.  
 
The efficiency of the THP-1 protein knockouts was also verified by quantitative RT-
PCR.Briefly, this was accomplished by lysing 2 x106cells andisolating total RNA using a 
QiagenRNeasy® kite RNA.Total RNA amount was measured by NanoDrop. 
200 ng total RNA was reverse transcribed to cDNA using Superscript III® with Oligo-dT 
as primer.  RT qPCR was performed using a Maxima® SYBR green kit. Obtained 
mRNA was calculated by normalising it to amount per GAPDH cDNA which was 
included in the run (GAPDH forward and reverse primer sequences 
CAAGATCATCAGCAATGCCT and AGGGATGATGTTCTGGAGAG respectively). 
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2.3 THP-1 differentiation to macrophage phenotype 
2 x106 normal THP-1 cells and knockouts were differentiated to a macrophage phenotype 
by adding Phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich),at a final 
concentration of 100nMand incubated for 24 – 48 hours (hrs) under 370C, 5% CO2 and 
>80% humidity. The PMA-containing media was subsequently aspirated and the now 
adherent cells lifted with 0.25% Trypsin-EDTA (Life Technologies), counted, and 
transferred to a flat-bottom 96 well culture plate at a concentration of 1 x105 cells/well in 
triplicate. The cells were further incubated for 24 – 48hrsin fresh RPMI 1640/10% FBS 
media before infection with virus at multiplicity of infection (MOI) of 1 or MOI of 0.3, or 
performing mock-infections.  
2.4 Making infectious HIV-2proviral clones 
The vector HIV-2 ROD 9 ΔenvΔnefGFP+and theHIV-2 ROD 9 
ΔenvΔnefGFP+Δvpxplasmidsweregenerously offered by Dr. Masa Yamashita of the 
Aaron Diamond AIDS Research Centre, New York; and was generated by cloning a 
gfpgenein place of the viral nef of the infectious proviral expression plasmid HIV-2 
ROD9 pKP59. The plasmid encodes the whole genome oftheHIV-2 ROD 9 reference 
strain (GeneBank: M15390.1). 
2.5 Generating HIV-2 ROD 9 mutants 
The HIV-2 ROD9 ΔenvΔnefGFP+Δvpr mutants used for this work were primarily made 
by a cloning strategy employing the restriction enzymes HIND III, BCL-I, Sal I and 
BsmB I (all New England Biolabs®). Briefly, a BCL-I/HINDIII fragment of 
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approximately 1.1kb overlapping the vprgene of the reference HIV-2 strain was cloned 
into the vector plasmid pSL1180 (Pharmacia); with subsequent amplification in 
Escherichia coli (E.coli) strain Stable II (STBL II). The cloned DNA was subsequently 
purified and eluted using the Maxi Purelink™ (Thermo Fisher) kit. 
 
Site-directed mutagenesis of the cloned fragment was done using the QuickChange II™ 
kit (Agilent Technologies, Santa Clara, CA, USA)using a sense primer (Invitrogen) with 
sequence 5’-CAGGTCTGGTCTAAGGGCTTAAGCACCAACAGAGC  to substitute a 
single base at the ATG start site of the vpr gene; and an antisense primer (Invitrogen) of 
sequence 5’-GCTCTGTTGGTGCTTAAGCCCTTAGACCAGACCTG to amplify the 
mutated region of the gene by polymerase chain reaction (PCR). The reaction was hot-
started at 950C ramp temperature for 30 seconds (s), followed by denaturation at 950C, 
30s; primer annealing at 550C for 1 minute (min) and strand extension at 680C for 5 min 
and 30s. The reaction was repeated for 18 cycles.  
The single-base substitution at the ATG start codon of the vpropen reading 
frameabrogatedthe viral gene expression. Successful mutation was verified by subsequent 
nucleotide sequencing using Vpr-Vpx sense (forward) primer 5’-
TGTCCTGCTGCAATTATC-3’(Invitrogen), and Vpr-Vpx antisense (reverse) primer 5’-
CTTTCGTTCATAACATATC-3’(Invitrogen). 
The PCR amplicon was transduced into STBL II with carbenecillin selection in LB broth. 
The mutated purified DNA was then digested by the restriction enzymes Hind III, Sal I, 
and BCL I; generating fragments of sizes approximately 4, 6.5, and 1.3 kb. The original 
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reference strain was digested with the same enzymes. A three restriction fragment 
ligation was subsequently done to clone the 4kb and 6.5 kb fragments from the reference 
HIV-2 strain to the 1.3kb mutated fragment overlapping vpr.  
The cloned DNA was sequenced to confirm insertion of the mutated fragment using the 
same primers stated. Following confirmation of successful mutation of HIV-2 vpr, the 
DNA fragment was cloned into the HIV-2 ROD 9 ΔenvΔnefGFP+plasmid using the 
restriction sites for Bcl-I and BsmB I. It is this clone that was then used for making the 
infectious provirus, as described below, for the experiments. 
2.6 Making virus stocks for THP-1macrophage infection 
Virus stocks were made using the method as described by Pear and colleagues32 using 
calcium chloride (CaCl2) in place of calcium phosphate.Briefly,15ug total of the purified 
DNA constructs (13.5 ug and 1.5 ug of HIV-2 and vesicular stomatitis virus glycoprotein 
(VSV/G) envelope pcDNA-plasmids respectively)was transfected into 2.5 x106 HEK 
293T cells in a plastic 10cm3 cell culture petri dish with 10 mL DMEM.TheCaCl2 was 
washed off, after 12 -15 hrs of incubation at conditions as stated above, with sterile, 
calcium- and magnesium-free Dulbecco’s Phosphate Buffered Saline, DPBS (Life 
Technologies) and replaced with fresh DMEM.  
Plates were further incubated for 24 hours before virus was concentrated through 20% 
sucrose/PBS and titrated in TZMBlreportercells by X-gal blue color technique as 
previously described. Virus stocks were frozen in 20uL aliquots at -80°C. 
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2.7 Flow cytometry 
Flow cytometric measurements were performed using a four color FACSCalibur (Becton 
Dickinson). Forward and side scatterwas used to identify macrophage-like cell 
populations bysizeand granularity. The number of GFP+ cellsin infected cultures was 
determinedby gating using mock (uninfected) cells. This was after the test cells had been 
infected with the respective HIV-2 proviral constructs at either MOI of 1 or 0.3, 
spinoculated and cultured for 24 – 48 hrs, before washing with DPBS, adding trypsin and 
washing again with RPMI 1640 followed by DPBS; and finally fixing with 2% 
Paraformaldehyde, PFA (Boston Bioproducts) in DPBS. 10,000 acquisition events were 
recorded on the cytometer using the Forward Scatter (FSC)/Side Scatter (SSC) 
population gating strategy in BD Cell Quest Pro™ software. 
2.8 Statistical Analysis 
Percentage infectivity data was analysedbyFlowJo™ software, version 8.8.4 (Tree Star 
Inc.version 10.1, Ashland, OR, USA) to generate dot plots. Productive virus infection 
was recorded as infectious particles per microliter. All raw data was exported into 
spreadsheets for statistical testing analysis of variance using Kruskal-Wallis multiple-
comparison Z-value test. The test was used to determine differences in virus infectivity 
within the different THP-1 macrophage conditions using the software IBM SPSS® (New 
York, USA). The statisticaltests are recorded as mean + standard error of the mean(SEM) 
unless otherwise stated. Significance was defined asp<0.05. 
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CHAPTER 3 
RESULTS 
3.1 Insufficient gene knockdown of THP-1 macrophage GBP5 gene 
 
To elucidate the antiviral effects of the host restriction factors GBP5 and Sp110 in THP-1 
macrophages, we used shRNA to knock-down mRNA levels of these proteins, and make 
comparisons with normal THP-1 macrophages. While Sp110 expression was dramatically 
reduced in the cells, we were unable to sufficiently knock down GBP5 to completely 
abrogate its function (Figure 1.) 
 
 
Figure 1. Relative Expression Levels of GBP5 and Sp110 mRNA in normal THP-1 
cell line and gene knock downs.Lentivirus containing small hairpin RNA genes to bind 
and degrade GBP5 and Sp110 gene products was used to transfect THP-1 cells. Knock-
down of Sp110, but not GBP5, gene expression was sufficiently achieved. 
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3.2 HIV-2 infectivity of THP-1 macrophages tends to increase in the absence of Vpr 
We assessed infectivity of VSV-G pseudotypedHIV-2ΔenvΔnef GFP+ virusesin THP-1 
macrophages. There was a marginal increase ofHIV-2ΔenvΔnef GFP+ virus infectivity of 
THP-1 macrophages in the absence of Vpr (Figure 2); while deletion of the Vpxgene 
dramatically reduced virus infectivity in THP1/PMA cells, consistent with previously 
published findings.33,34 
Error plot – assess the mean 
infectivity between the viruses in 
all cell lines
 
Figure 2: Change in Mean percent infectivity of VSV-G pseudotyped HIV-
2ΔenvΔnef GFP+ virus in THP-1 macrophages. Plot of change in mean percent 
infectivity HIV-2ΔenvΔnefGFP+ wild type (HIV-2WT), HIV-2ΔenvΔnefΔvprGFP+ 
(HIV-2delVPR), and HIV-2ΔenvΔnefΔvpxGFP+ (HIV-2delVPX) percent infectivity 
across THP-1 macrophages. 
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3.3 Macrophage gene Sp110 knock down affects HIV-2ΔenvΔnef GFP+ infectivity 
Knockdown of the macrophage restriction factor Sp110 resulted in a decrease in HIV-2 
wild type and HIV-2delvpr GFP+ viruses’ infectivity of the cells [Figure 3. (A)and (B)]. 
In contrast, reduction of Sp110 expression in the THP-1 macrophages was associated 
with an increase in the infectivity of HIV-2delvpx mutant [Figure 3. (C)].
error plot – assess the mean 
infectivity of HIV2 WT in the cell 
lines
 
Figure 3: (A). Mean +/- 
2 SE percent infectivity 
of HIV-2ΔenvΔnef 
GFP+ Wild Type (WT) 
infectivity in THP-1 
normal and gene 
knockdown 
macrophages. 
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error plot – assess the mean 
infectivity of HIV2 del VPR in the 
cell lines
 
error plot – assess the mean 
infectivity of HIV2 del VPX in the 
cell lines
Figure 3: Mean percent infectivity of HIV-2ΔenvΔnefGFP+ Wild Type (HIV-2WT), 
(A), HIV-2ΔenvΔnefΔvprGFP+ (HIV-2delVPR), (B), and HIV-
2ΔenvΔnefΔvpxGFP+ (HIV-2delVPX), (C), inTHP-1 normal and knock down 
macrophages. Individually comparing the mean percentage infection of each virus in 
each THP-1 macrophage condition revealed decreases in the infectivity of HIV-2 WT and 
HIV-2delVPR in Sp110 knockdown THP-1 macrophages. In contrast, there was an 
increase of HIV-2 delVPX percent infectivity in the same cells. Virus infectivity was 
measured by FACS analysis for GFP+ particles at48 hours post infection. 
Figure 3: (B). Mean +/- 2 SE 
percent infectivity of HIV-
2ΔenvΔnefΔvprGFP+ (HIV-2 
delVPR) infectivity in THP-1 
normal and gene knockdown 
macrophages. 
 
Figure 3: (C). Mean 
infectivity of HIV-
2ΔenvΔnefΔvpxGFP+ 
(HIV-2 delVPX) 
infectivity in THP-1 
normal and gene 
knockdown 
macrophages. 
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3.4 Increased infectious HIV-2 virus release from macrophages with knockdown 
Sp110 
We next determined the effect of Sp110 knock-down on HIV-2 spread in THP1/PMA 
macrophage cultures. Mock uninfected, HIV-1 and HIV-2 infected THP1/PMA cell 
supernatants were harvested on day 3 and 6 post infection and added to TZMBl reporter 
cells. TZM-Bl cells were cultured for 2 -3 days and the extent of virus infection was 
determined by fixing and staining the cells for 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal), and by extension β-galactosidase, activity. The amount of 
infectious virus particles released from THP1/PMA cells was determined by counting the 
number of blue foci. Note that x-gal expression (number of blue foci) in TZMBl cells is 
directly correlated to the extent of virus infection.There was at least a log reduction in 
number of infectious HIV-1 particles released from Sp110 knockdown compared to 
normal macrophages over 6 days post infection [Figure 4 (A) and (B)]. No difference in 
HIV-1 virus production was observedbetween GBP5 knock down and normal 
macrophages in one experimentFigure 4 (A); but approximately 1.5 log decrease in HIV-
1 virus production from GBP5 knockout compared to normal macrophages 3 and 6 days 
post infection occurred in a follow up experiment(Figure 4B). 
Interestingly, reduced Sp110 expression corresponded to increased HIV-2 
productionfrom macrophages in one experiment (Figure 4A), but there was no difference 
in viral production between normal and Sp110 knock down macrophages by day 3 post 
infection in the follow up experiment. There was no virus production from the Sp110 
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knock down cells on day 6 in the follow up experiment(Figure 4B). HIV-2 virus 
production was also reduced in GBP5 knock down, relative to normal, macrophages 6 
days post infection [Figure 4 (A) and (B)]. Day 3 post HIV-2 infection indicated 
increased virus spread in GBP5 knockouts in one experiment, and decreased in the follow 
up experiment, relative to normal THP-1 macrophages. 
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Figure 4: Productive 
virus release in 
TZMBl. Infectious HIV-
1 Lai YU and HIV-2 
ROD9 strains released 
from macrophages into 
supernatant was 
collected at 3 and 6 days 
post infection. Virus 
tires were calculated by 
X-gal method and 
reported as infectious 
particles per microliter 
(IP/ul). Figure shows 
two independent 
experiments A and B. 
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CHAPTER 4 
DISCUSSION 
 
Comparison of GBP5 expression levels in THP-1 macrophages transduced with lentivirus 
VSV-G containing small hairpin RNA (shRNA) to knock down its expression revealed 
only approximately 12% reductionin gene expression (Figure 1). This was considered a 
negligible reduction in gene expression among transduced cells. We therefore used cells 
transduced with lentivirus containing GBP5 shRNA as surrogate controls for those 
transduced with Sp110 shRNA in subsequent analysis. The poor knock down of GBP5 
was probably a consequence of a poorly compatible bacterial stock plasmid clone 
selected from the vendor. A different clone will be selected for repeat experiments. 
 
Deletion of Vprin our study associated with an increase in HIV-2 infectivity of THP-1 
macrophages in all experimental conditions (Figure 2). This was measured by percentage 
of cells expressing the GFP gene inserted in place of the viral accessory protein nef. 
Collins and colleagues recently suggested that HIV-1 Vpr prevents the induction of Type 
1 interferon in macrophages.27 This results in failure to activate transcription of various 
interferon-dependent anti-pathogen effector genes, including GBP5 and Sp110. This 
could be a particularly important immune evasion mechanism for initial viral 
establishment within the hostile macrophage cell milieu in acute infection. Our 
observation, therefore, supports the argument that HIV-2, just like HIV-1, possibly 
utilizesVprto prevent sensing of virus infection in macrophages, thusallowing viral 
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replication without inducing interferon stimulation, and subsequent viral restriction.  The 
differences in disease severity between HIV-1/TB and HIV-2/TB coinfection may be a 
consequence of HIV-2 Vprnot functioning as well as HIV-1 Vprdue to factors such as 
more efficient HIV-2 replication in macrophages, resulting in exposure of higher levels 
of viral-associated molecular patterns. This increases opportunity of immune sensing of 
invading pathogen, and subsequent host cell response.  
 
Our results also suggest that the host macrophage restriction factor Sp110 may indeed 
enhance HIV-2 and HIV-2delVpr infectivity [Figure 3 (A) and (B)]. A knock down of the 
host gene Sp110 led to a reduction in percentage of GFP+ cells, though the differences 
were not significant. This is in agreement with the assertion by Mclaren and colleagues 
that macrophage Sp110 enhanced HIV-1 infectivity.16 The mechanism for this is still 
unclear, and would require further exploration. 
Interestingly, the HIV-2 Vpx mutant viral infectivity increased within THP-1 shSp110 
knockout cells compared to HIV-2 wild type and delVpr mutant viruses [Figure 3 (C)]. 
This could imply presence of a yet unknown association between another HIV-2 viral 
accessory protein, Vpx, and the macrophage restriction factor, Sp110, which is mostly 
known to counter invading intracellular bacteria such as Mycobacterium 
tuberculosis.15,16,35 
 
Knock down of Sp110 reduced the productive release of HIV-1 Lai YU-2 virions from 
the infected macrophages [Figure 4 (A) and 4 (B)]. These results were in agreement with 
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those from Mclaren and colleagues16, indicating that Sp110 promotes the infection of 
macrophages by HIV-1 by a factor of at least a log difference over 6 days in vitro. On the 
other hand, the slight knock down of GBP5 actually promoted HIV-1 infectious particle 
release into the supernatant to levels slightly higher than the normal THP-1 macrophages; 
another point of agreement with the Mclaren study that used HEK 293T cells.16 
HIV-2 ROD 9, however, presented mixed results. Apart from the very low titres of 
infectious virus particles released compared to HIV-1, knock down of Sp110 seemed to 
slightly increase the titre of virus particles released in one, but also decrease them, 
compared to normal THP-1 cells, in two independent experiments.  
The much lower titres of HIV-2 released compared to HIV-1 is surprising, particularly 
since HIV-2 has the Vpx accessory gene which has been showed to augment virus 
infection of myeloid cells.33,34 
In one experiment, HIV-2 mean infections particle release increased by at least 0.5 log, 
compared to infected normal THP-1 macrophages, when Sp110 was knocked down. This 
was the same trend both at day 3 and day 6 post infection [Figure 4 (A)]. However, in 
another experiment [Figure 4 (B)], there was no difference in the titres of HIV-2 virus 
particles produced by day 3 when Sp110 knock down THP-1 macrophages were 
compared to normal; and by day 6, we hardly detected any infectious particles released in 
the knock down cells.The results of the first virus spread (productive release) experiment 
contradicted what we observed when using pseudotyped single cycle infection virus to 
infect the macrophages in this same study, but those of the second concurred -we 
observed reduced levels of HIV-2 WT and HIV-2 Vpr mutant infectivity of THP-1 Sp110 
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knock downs [Figure 3(A) and 3(B)]. It is possible that Sp110 indeed does restrict both 
HIV-1 and HIV-2 viruses in much the same way as it does for bacterial pathogens,15,16 
but only transiently; and eventually is manipulated by the virus to promote viral 
replication. Subsequent work will verify this. 
It was also interesting to note that only a slight knock down of GBP5 reduced the number 
of HIV-2 viral particles released from the cells by almost a log difference from day 3 to 6 
in post infection in both infections [Figure 4 (A) and (B)]. Our results at day 3 were 
inconsistent for day 3 following HIV-2 infection of GBP5 knock down macrophages- 
showing increased viral production in one experiment, and a decrease in the follow up, 
relative to normal macrophages. 
These results together would be counter intuitive to the known role of GBP5 as a viral 
restriction factor,22 indicating that GBP5 too may initially restrict HIV-2 replication, but 
eventually become necessary for viral productive release from macrophages over a 
number of days. 
 
These observations point to different mechanisms of both GBP5and Sp110 interaction 
with the two HIV subtypes in macrophages and consequently differences in rate and 
efficiency of viral establishment. This subsequently may present as the clinically 
observed tempered pathogenesis of patients co-infected with HIV-2-TB compared to 
those infected with HIV-1-TB. Overall, our study further added to growing evidence that 
HIV-2, just like HIV-1, relies on its viral accessory protein Vpr, to mask its infection 
from the cell autonomous immune system of macrophages to allow virus establishment in 
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these cells. It also appears that the host restriction factor Sp110 may possibly play a role 
in restricting the late stages of HIV-2 replication although the mechanism is still unclear. 
Future work will aim to verify this mechanism. 
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